Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Patients Adhere Well to CFTR Therapies But High Costs Could Undermine Use, Pharmacy Study Says Vertex Reaches Agreement for CF Medications in Northern Ireland and Wales Patients Adhere Well to CFTR Therapies But High Costs Could Undermine Use, Pharmacy Study Says Nov 15, 2019 07:00 am | Ana Pena, PhD People with cystic fibrosis (CF) show a “high adherence” to CFTR modulators, but these newer medications are costly and could undermine compliance to treatment over time, according to a joint studies by AllianceRx Walgreens Prime and Duquesne University School of Pharmacy. These findings were presented at the recent Academy of Managed Care Pharmacists (AMCP) Nexus in Maryland […] The post Patients Adhere Well to CFTR Therapies But High Costs Could Undermine Use, Pharmacy Study Says appeared first on Cystic Fibrosis News Today. Read More Vertex Reaches Agreement for CF Medications in Northern Ireland and Wales Nov 14, 2019 07:00 am | Marisa Wexler MS The Regional Pharmaceutical Procurement Service in Northern Ireland and the National Health Service (NHS) Wales have reached an agreement with Vertex Pharmaceuticals that will allow people with cystic fibrosis (CF) who live there to access all of Vertex’s currently approved medications for the disease. The terms of the two agreements are the same as those recently […] The post Vertex Reaches Agreement for CF Medications in Northern Ireland and Wales appeared first on Cystic Fibrosis News Today. Read More Recent News Rare Disease Film Festival Highlights Patient and Researcher Unity Inspiration for Hire: Sick Candidates Only Proteostasis Therapeutics Completes Enrollment in Phase 2 Study Testing Triple Combination Therapy in Cystic Fibrosis Latinos on 2 Caribbean Islands Carry CFTR Mutations Seen in 1% of CF Patients Elsewhere, Study Says Addressing the Issues that Trikafta Benefits Will Bring